Search Medical Condition
Please enter condition
Please choose location from dropdown

Cesson Sevigne Cedex, France Clinical Trials

A listing of Cesson Sevigne Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (452) clinical trials

A Trial of Obinutuzumab GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

The study will be conducted into 3 steps for respecting the optimal safety of the OASIS trial Step A : The primary objective of step A is to evaluate the safety of the combination of GA101 + Ibrutinib at fixed doses (560 mg per day of Ibrutinib + 1000 mg ...

Phase

3.3 miles

Learn More »

If you’ve been unable to control your blood pressure, or are interested in an alternative to daily medications, you may be a candidate for the RADIANCE-HTN Clinical Study. The investigational study is evaluating a minimally-invasive, catheter-based procedure (the Paradise® Renal Denervation System) which may lower your blood pressure and reduce ...

Phase N/A

3.3 miles

Learn More »

Biomechanical and Morphological Changes in Dystrophic Muscle

The loss of ability to walk in many children with DMD (Duchenne muscular Dystrophy) is a pejorative event. Biomechanical and morphological unknowledge about the loss of the walk ability in children with DMD is an obstacle in reeducative, pharmacological or surgical therapeutic targets. We suppose that there are muscular characteristics ...

Phase N/A

3.3 miles

Learn More »

Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease with synovial tropism, characterized by joint pain and swelling, secondary to inflammation of the synovial membrane and which can lead to joint destruction, with the risk of a major functional disability. Biological treatments have revolutionized its management over the past 15 years. ...

Phase N/A

3.3 miles

Learn More »

Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) is the primary cause of lower urinary tract symptoms (LUTS) and affects > 50% of men >60 years. Moderate to severe symptoms prevalence is around 14% in France, and the proportion of men with moderate to severe symptoms doubles with each decade of age. The first-line ...

Phase

3.3 miles

Learn More »

Biological Characterisation of High Risk CHildhood Cancer in Children Adolescents and Young Adults (MICCHADO)

To identify and characterise: meaningful molecular genetic alterations, meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).

Phase N/A

3.3 miles

Learn More »

A clinical research study called 'POINT' will evaluate if adding an oral study drug to Tecfidera® can have an effect on multiple sclerosis (MS) disease activity. In this study, patients with active relapsing MS will receive add-on therapy with ponesimod (a sphingosine 1-phosphate [S1P] receptor modulator) or placebo on top ...

Phase

3.3 miles

Learn More »

OSS-IRM: Optimization of MRI Sequences in Healthy Volunteers

Using MRI, many technical parameters (sequence, parameters in the sequence, reconstruction method, etc.) can be changed to optimize the diagnostic quality of the examination. The primary objective of this study is to optimize the imaging protocols and to validate the choice of the technical parameters in healthy volunteers. The quality ...

Phase N/A

3.3 miles

Learn More »

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Phase

3.3 miles

Learn More »

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: relapsed/refractory follicular lymphoma (FL) patients relapsed/refractory aggressive (DLBCL) lymphoma patients relapsed/refractory other indolent (iNHL) ...

Phase

3.3 miles

Learn More »